Inventor · disambiguated record
Brendan J. Classon
Also filed as: CLASSON BRENDAN · CLASSON BRENDAN J
14 granted patents·1 pending application·247 citations·filing 2009–2022
93Inventor score
Top patents by PatentIndex Score
15 records- 0195US9228014B2Antibodies capable of blocking the interaction between CD48 and a CD48 receptorCLASSON BRENDAN J·Filed 2011·Granted Jan 5, 2016·78 cites·21 claims
- 0294US9556277B2Method of treating a TL1A-associated disease or disorder with human antibodies to TL1AREGENERON PHARMA·Filed 2013·Granted Jan 31, 2017·25 cites·7 claims
- 0394US9290574B2Methods for treating eosinophilic esophagitis by administering an IL-4R inhibitorREGENERON PHARMA·Filed 2014·Granted Mar 22, 2016·32 cites·46 claims
- 0493US10730948B2Methods for treating eosinophilic esophagitis by administering an IL-4R inhibitorREGENERON PHARMA·Filed 2016·Granted Aug 4, 2020·16 cites·20 claims
- 0593US8454959B2Compositions monovalent for CD28 binding and methods of useMCKINNON MURRAY·Filed 2012·Granted Jun 4, 2013·23 cites·11 claims
- 0693US8168759B2Compositions monovalent for CD28 binding and methods of useMCKINNON MURRAY·Filed 2009·Granted May 1, 2012·21 cites·13 claims
- 0792US9085629B2Compositions monovalent for CD28 binding and methods of useMCKINNON MURRAY·Filed 2012·Granted Jul 21, 2015·18 cites·29 claims
- 0892US8642741B2Human antibodies to human TNF-like ligand 1A (TL1A)CLASSON BRENDAN J·Filed 2011·Granted Feb 4, 2014·24 cites·13 claims
- 0991US11421036B2Methods of treating eosinophilic esophagitis by administering an antibody which inhibits interleukin-4 receptor (IL-4R)REGENERON PHARMA·Filed 2020·Granted Aug 23, 2022·2 cites·16 claims
- 1091US10919965B2Compositions monovalent for CD28 binding and methods of useBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Feb 16, 2021·3 cites·18 claims
- 1188US9908937B2Compositions monovalent for CD28 binding and methods of useBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Mar 6, 2018·5 cites·22 claims
- 1279US12291571B2Methods for reducing eosinophilic infiltration by administering an anti-interleukin-4 receptor (IL4R) antibodyREGENERON PHARMA·Filed 2022·Granted May 6, 2025·0 cites·27 claims
- 1376US12012452B2Compositions monovalent for CD28 binding and methods of useBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Jun 18, 2024·0 cites·20 claims
- 1451US2017096491A1Human antibodies to human tnf-like ligand 1a (tl1a)REGENERON PHARMA·Filed 2016·Application pending·0 cites
- 1547US9533039B2Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodiesREGENERON PHARMA·Filed 2013·Granted Jan 3, 2017·0 cites·14 claims
Join the waitlist — get patent alerts
Get an alert when Brendan J. Classon files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →